临床外科杂志 ›› 2023, Vol. 31 ›› Issue (9): 852-855.doi: 10.3969/j.issn.1005-6483.2023.09.015

• 论著 • 上一篇    下一篇

肝癌病人血清中长链非编码RNA BSN-AS2、hsa-miR-4782-3p表达水平及其临床诊断价值分析

  

  1. 430100 武汉市蔡甸区人民医院/协和江北医院检验科(罗兴红、杨柳);武汉市黄陂区人民医院盘龙院区检验科(董琪);湖北文理学院附属医院,襄阳市中心医院消化内科(田爱霞、龙丹)
  • 收稿日期:2022-11-10 出版日期:2023-09-20 发布日期:2023-09-20
  • 通讯作者: 龙丹,Email:kvggf03@163.com
  • 基金资助:
    湖北省自然科学基金资助项目(WJ2018Z0119)

Expression levels and clinical diagnostic value of lncRNA BSN-AS2 and hsa-miR-4782-3p in serum of patients with liver cancer

  1. Department of Laboratory,Wuhan Caidian District People’s Hospital,Xiehe Jiangbei Hospital,Hubei Province,Wuhan 430100 China
  • Received:2022-11-10 Online:2023-09-20 Published:2023-09-20

摘要: 目的 检测肝癌病人血清中长链非编码RNA BSN-AS2(lncRNA BSN-AS2)、hsa-miR-4782-3p表达水平,并分析两者在肝癌中的临床诊断价值。方法 选取2018年3月~2020年3月在我院诊治的肝癌病人100例为研究组,另取同期体检健康者90例为对照组。采用实时定量聚合酶链式反应法(qRT-PCR)检测病人血清中lncRNA BSN-AS2、hsa-miR-4782-3p的表达水平;采用Spearman等级相关分析血清中lncRNA BSN-AS2与hsa-miR-4782-3p表达的相关性,同时分析二者与临床病理特征的关系;受试者工作特征(ROC)曲线分析血清lncRNA BSN-AS2、hsa-miR-4782-3p表达水平对肝癌的诊断效能。结果 研究组血清lncRNA BSN-AS2的表达水平为(2.02±0.59),显著高于对照组的(1.05±0.25),研究组血清hsa-miR-4782-3p的表达水平为(0.69±0.15),低于对照组的(1.08±0.29),两组比较差异有统计学意义(P<0.05)。血清lncRNA BSN-AS2、hsa-miR-4782-3p表达水平与TNM分期、分化程度、甲胎蛋白(AFP)有关(P<0.05)。Spearman等级相关分析显示,肝癌病人血清lncRNA BSNAS2与hsa-miR-4782-3p表达呈负相关(r=-0.536,P<0.05)。血清lncRNA BSN-AS2、hsa-miR-4782-3单独及联合诊断肝癌的AUC分别是0.890、0.856和0.937,灵敏度分别为87.00%、93.00%和86.00%,特异度分别为78.89%、70.00%和92.22%;二者联合优于lncRNA BSN-AS2、hsa-miR-4782-3p各自单独预测(二者联合-lncRNA BSN-AS-=2.481、P=0.013,二者联合-hsa-miR-4782-3P=3.503,P=0.001)。结论 肝癌病人血清lncRNA BSN-AS2表达水平显著升高,hsa-miR-4782-3p水平显著降低,可作为诊断肝癌的潜在分子标志物。

关键词: 肝癌, 长链非编码RNA BSN-AS2, hsa-miR-4782-3p, 临床诊断

Abstract: Objective To detect the expression levels of long non-coding RNA BSN-AS2 (lncRNA BSN-AS2) and hsa-miR-4782-3p in serum of patients with liver cancer,and to analyze their clinical diagnostic value in liver cancer.Methods A total of 100 patients with liver cancer who were diagnosed and treated in our hospital from March 2018 to March 2020 were taken as the research group.Another 90 healthy subjects who underwent physical examination were included as the control group.Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression levels of lncRNA BSN-AS2 and hsa-miR-4782-3p in serum of patients;Spearman rank correlation was applied to analyze the correlation between the expression of lncRNA BSN-AS2 and hsa-miR-4782-3p in serum,meantime,the relationship between the two and clinicopathological characteristics was analyzed;receiver operating characteristic (ROC) curve was applied to analyze the diagnostic efficacy of serum lncRNA BSN-AS2 and hsa-miR-4782-3p expression levels for liver cancer. Results The results of qRT-PCR showed that the expression level of serum lncRNA BSN-AS2 in the study group (2.02±0.59) was obviously higher than that in the control group (1.05±0.25),the expression level of serum hsa-miR-4782-3p in the study group (0.69±0.15) was obviously lower than that in the control group (1.08±0.29) (P<0.05).The expression levels of serum lncRNA BSN-AS2 and hsa-miR-4782-3p were related to TNM staging, alpha-fetoprotein (AFP) and degree of differentiation (P<0.05).Spearman rank correlation analysis showed that serum lncRNA BSN-AS2 was negatively correlated with the expression of hsa-miR-4782-3p in patients with liver cancer (r=-0.536,P<0.05).The AUC of serum lncRNA BSN-AS2 and hsa-miR-4782-3 alone and in combination for diagnosing liver cancer was 0.890,0.856 and 0.937,respectively,the sensitivity was 87.00%,93.00% and 86.00%,and the specificity was 78.89%,70.00%and 92.22%,respectively;the combination of the two was better than the prediction of lncRNA BSN-AS2 and hsa-miR-4782-3p,respectively (the combination of the two-lncRNA BSN-AS-=2.481,P=0.013the combination of the two-hsa-miR-4782-3P= 3.503,P=0.001).Conclusion The expression level of serum lncRNA BSN-AS2 in patients with liver cancer is obviously increased,and the level of hsa-miR-4782-3p is obviously decreased,both can be used as potential molecular markers for the diagnosis of liver cancer.

Key words: liver cancer, long non-coding RNA BSN-AS2, hsa-miR-4782-3p, clinical diagnosis

[1] 徐仁良 沈松柏 余龙伍 华双一 吴扬 徐标 李春. 载药微球经动脉化疗栓塞与传统肝动脉化疗栓塞分别联合索拉非尼治疗中晚期肝细胞肝癌的有效性和安全性对比[J]. 临床外科杂志, 2023, 31(4): 383-386.
[2] 蔡秀军 陈鸣宇 曹佳胜 张斌. 美国国立综合癌症网络临床实践指南:肝胆癌(2022.V2)更新解读[J]. 临床外科杂志, 2023, 31(1): 11-13.
[3] 罗恒 卫向红 吴清明 向世强 张若涵. 低密度脂蛋白和高密度脂蛋白亚类鉴定在乙型肝炎病毒相关性肝癌发生风险预测中的意义[J]. 临床外科杂志, 2022, 30(9): 875-879.
[4] 杨刚 王冠 熊永福 李芸 雷蓉 柳弥. 肝癌调控细胞凋亡抑制因子1的表达及其对细胞增殖和凋亡的影响[J]. 临床外科杂志, 2022, 30(5): 471-474.
[5] 罗朝霞 夏辉 龚昭 姚磊. 肝动脉化疗栓塞联合阿帕替尼治疗中晚期肝癌有效性和安全性Meta分析[J]. 临床外科杂志, 2022, 30(12): 1129-1132.
[6] 宇汝胜 童钟 段胜 王晓刚 郑吉顺 胡启立. 前S1抗原与乙型肝炎表面抗原比值预测乙型肝炎病毒相关肝硬化病人肝癌发生风险的价值分析[J]. 临床外科杂志, 2022, 30(11): 1044-1047.
[7] 蔡秀军 张斌 陈鸣宇 曹佳胜. 美国国家综合癌症网络肝胆肿瘤临床实践指南2021.V2版更新解读(肝癌部分)[J]. 临床外科杂志, 2022, 30(1): 4-6.
[8] 李江, 陈耀兵, 陈丽君等. 自体肿瘤浸润淋巴细胞联合抗程序性死亡受体1单抗治疗晚期肝癌的临床研究[J]. 临床外科杂志, 2021, 29(8): 743-747.
[9] 孙启刚, 符策雄, 郑进方. 绕肝悬吊前入路右半肝切除术在肝癌手术中的应用研究[J]. 临床外科杂志, 2021, 29(8): 748-750.
[10] 潘乐玉, 郭德良, 张玉仙等. 肝动脉结扎联合门静脉部分阻断对肝再生及肝细胞癌生长的影响[J]. 临床外科杂志, 2021, 29(4): 367-371.
[11] 王观宇. 肝癌转化治疗的策略和现状[J]. 临床外科杂志, 2021, 29(11): 1012-1014.
[12] 方小三 王小明 韩婷 蒋彬 王冠男 奚士航. 原发性肝癌病人腹腔镜肝叶切除术后并发胆漏的风险预测模型构建[J]. 临床外科杂志, 2021, 29(11): 1030-1033.
[13] 李柱威 尹东亮 黎笑兰 王金林 林志强 卢沛林 尹润龙. 预存式自体输血对肝癌手术病人炎症反应及免疫功能的影响[J]. 临床外科杂志, 2021, 29(11): 1034-1037.
[14] 郭张有 洪源. 肝硬化门静脉高压症肝癌手术切除全程评估和管理的进展[J]. 临床外科杂志, 2021, 29(11): 1092-1095.
[15] 郭杨 韩磊 常轶群 吴军 张巍. 原发性肝癌合并先天性右侧膈肌缺损行肝部分切除术一例[J]. 临床外科杂志, 2021, 29(11): 1099-1100.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!